Therefore, the present study provides the first evidence for wild-type p53 constituting an attractive therapeutic target for aggressive meningiomas and CEP-1347 representing a valid choice for the purpose of targeting p53 in these tumors. This evidence concerns the gene TP53 and meningioma.